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introduction: The incidence of deep infection using a synthetic mesh in inguinal hernia 
repair is low and reported to be well below 1%. This is in contrast to incisional hernia 
surgery where the reported incidence is 3% respective 13% comparing laparoscopic to 
open mesh repair reported in a Cochrane review. Main risk factors were long operation 
time, surgical site contamination, and early wound complications. An infected mesh 
can be preserved using conservative treatment were negative pressure wound therapy 
(VAC®) could play an important role. If strategy fails, the mesh needs to be removed. This 
review aims to look at evidence for situations were a biological mesh would work as a 
replacement of a removed infected synthetic mesh.
Materials and methods: A literature search of the Medline database was performed 
using the PubMed search engine. Twenty publications were found relevant for this review.
Results: For studies reviewed three options are presented: removal of the infected 
synthetic mesh alone, replacement with either a new synthetic or a new biological mesh. 
Operations were all performed at specialist centers. Removal of the mesh alone was 
an option limited to inguinal hernias. In ventral/incisional hernias, the use of a biological 
mesh for replacement resulted in a very high recurrence rate, if bridging was required. 
Either a synthetic or a biological mesh seems to work as a replacement when fascial 
closure can be achieved. Evidence is though very low.
Conclusion: When required, either a synthetic or a biological mesh seems to work as 
a replacement for an infected synthetic mesh if the defect can be closed. It is, however, 
not recommended to use a biological mesh for bridging. Mesh replacement surgery is 
demanding and is recommended to be performed in a specialist center.
Keywords: hernia, mesh infection, biological mesh, mesh replacement, mesh complication
inTRODUCTiOn
Reduced recurrence rates can be achieved by using standardized surgical techniques for mesh rein-
forcement in hernia surgery (1–3). Accordingly, several different types of meshes are used worldwide 
in hernia surgery. In the US alone, some 800,000 inguinal hernia (4) and 400,000 ventral hernia, 
including primary and incisional (5), operations are performed annually. In Sweden, 16,000 inguinal 
TABLe 1 | Characteristics and outcomes of studies reporting on replacement of infected synthetic meshes with either a synthetic or biologic mesh in 
ventral/incisional hernia repair.
Reference Study design Patients (n) Mesh for replacement intervention details Follow-up 
time
Outcome
Birolini et al. (15) Retrospective case 
series
41 HW PP Single stage 74 months 27 uneventful
Single surgeon 10 (24%) inf
Onlay 1 mesh removal
3 recur
1 EC fistula
Albino et al. (5) Retrospective cases 
series
27 PADM Two stages 32 months 6 wound rupt
6 bridging 5 inf
5 (19%) recur (all bridged rep)
Rosen et al. (16) Retrospective case 
series
128 in total 102 Strattice Single stage 22 months 61 (48%) inf
45 (35%) inf* 16 Alloderm 87 rr mesh 28 major
5 Biodesign 40 ip mesh 33 minor
4 Xenmatrix 70% comp sep 40 (31%) recur
4 BioA 6% bridging
Guerra (17) Retrospective case 
series
13 PADM® Single stage 22 months 1 inf
2 bridged 1 seroma
2 recur (both bridged repairs)
Cavallaro et al. (18) Case report 2 Bovine pericardium graft Single stage 5 years 0 inf
rr 0 recur
Peppas et al. (19) Case report 1 EC fistula Porcine tissue Two stages 6 months 0 inf
Two meshes Collamend® 0 recur
PTFE and PP
Coccolini et al. (20) Case report 2 Collamend®
Surgisis
Single stage 36 months 0 inf
0 recur
HW = heavy weight, PP = polypropylene, PTFE = polytetrafluoreten, rr = retro rectus, ip = intra peritoneal, PADM = porcine acellular dermal matrix, mo = months, inf = infection, 
recur = recurrence, rupt = rupture, EC = enterocutanous, rep = repair.
*Mesh infections cannot be identified for individual meshes.
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and 7,000 ventral hernias are reported on an annual basis in the 
national registers. In Germany, 275,000 inguinal and 100,000 
ventral hernia operations are carried out annually.
In a review (6), the reported incidence of mesh-related 
infections following hernia repair was between 1 and 8% in 
different series. The incidence was influenced by the underly-
ing comorbidities, type of mesh, surgical technique, and the 
strategy used to prevent infections. Risk factors to determine 
the onset of mesh infection were a prolonged operation time (7, 
8), the extent of contamination of the surgical site (9), and early 
complications of the wound (seroma, hematoma, and infection) 
(8). In the Cochrane review of laparoscopic versus open surgical 
techniques for ventral or incisional hernia repairs, the overall 
infection rate was 13% after open and 3% after laparoscopic 
mesh repair (10).
Prevention of mesh infections continues to be the best 
strategy (11). Not all infections necessitate mesh removal. In 
the Cochrane review, only 3.3% of meshes had to be removed 
following open and 0.7% following laparoscopic ventral and inci-
sional hernia repairs (10). It was possible to preserve 17 (55%) 
of meshes through conservative treatment in a case series of 31 
infected meshes after incisional hernias repair (7). In a study 
on in ventral hernia repairs by Liang et al., a total of 30 out of 
407 (7.4%) were re-operated due to an infection and the mesh 
could be saved in 10 out of these 30 (33%) (9). Reoperations 
were performed evenly spread from operation up to 10  years 
after the primary operation. In another series, it was possible 
to preserve 12 out of 13 (92%) were VAC® was used in addition 
in 11 patients (12). The rate of mesh removal due to infection 
following inguinal hernia repairs was reported to be 0.13% (13). 
The interval between hernia operation and mesh removal could 
be up to 10 years or longer.
In a review by Darehzereshki et al. including eight retrospec-
tive studies, with a total of 1,229 patients comparing different bio-
logical to synthetic mesh repair in ventral and incisional hernias. 
It was demonstrated that biological grafts were associated with 
significantly fewer wound infections (p < 0.00001) but with no 
difference in recurrence rate (14).
The aim to look at evidence for situations were a biological 
mesh would work as a replacement of a removed infected syn-
thetic mesh.
MATeRiALS AnD MeTHODS
A literature search of the Medline database was performed using 
the PubMed search engine. The following key words were used: 
biological mesh, replacement of infected mesh, ventral hernia 
AND infected mesh, inguinal hernia AND infected mesh, mesh 
infection AND biological mesh, infected synthetic mesh AND 
biological mesh. Two thousand five hundred one citations were 
found. After checking the title and abstracts, 20 publications 
remained included in this study. Seven of these publications, four 
case series and three case reports, do report on the replacement 
of a synthetic by a biological mesh (Table 1).
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The treatment options were removal of the infected mesh 
alone, replacement of the infected with a new synthetic mesh, 
and replacement of an infected synthetic with a biological mesh.
ReSULTS
Removal of the infected Mesh Alone
In the following two studies, a total of 47 patients with mesh 
infection were treated by means of partial or complete mesh 
removal. Neither a synthetic nor a biological mesh was implanted 
to replace the explanted mesh.
In a retrospective case series by Akyol et al., 15 mesh removals 
were performed after inguinal hernia repair because of chronic 
mesh infection in 14 males and 1 female with a median age 
of 52  years (range 35–75  years) (13). At the time of presenta-
tion, 13 patients had chronic sinus at explanation, while 2 had 
abscesses. The interval from hernia repair to mesh removal was 
4–204 months. The infected meshes were completely removed. 
None of the patients had the transversalis fascia reinforced, due 
to thickening by fibrosis from the former mesh. Follow-up was 
performed median 62 months (range 16–115 months). Infection 
resolved successfully in all patients. One patient reported pares-
thesia and another developed a recurrent hernia.
In a retrospective case series by Tolino et al., 32 mesh remov-
als were performed due to chronic infection, 22 after incisional 
and 10 after inguinal hernia repair (8). The interval from repair 
to mesh removal ranged from 4 to 60  months. A total of 51 
operations in the 32 patients were needed for definitive treatment, 
including partial or total mesh removal. The average follow-up 
was 40 months (range 30–97). Five hernia recurrences and one 
intestinal fistula were observed after incisional mesh removal. 
One recurrence and one fistula developed after inguinal hernia 
mesh removal.
Replacement of the infected with a new 
Synthetic Mesh
In a single surgeon case series by Birolini et  al., a 16-year ret-
rospective review based on a prospective protocol was carried 
out in 41 patients having had ventral hernias surgery with their 
meshes removed (15). A total of 27 patients had a supportive 
infection and 14 had an exposed mesh. Bowel resection or an 
associated contaminated procedure was performed in 15 patients. 
An onlay polypropylene mesh was used for replacement in all 
patients. In the short-term follow-up, all, except one mesh, could 
be preserved. Three recurrences were seen after a mean follow-up 
of 74 months, out of which one was associated with an intestinal 
fistula. A total of 95% of the patients were considered cured from 
their chronic mesh infection. It was concluded that onlay poly-
propylene mesh yielded favorable outcomes, for high-risk ventral 
hernia patients, having an infected synthetic mesh removed in a 
single-stage repair setting.
Replacement of the infected with a 
Biological Mesh
In the following six studies (three case series and three case 
reports), a total of 92 patients with mesh infection were treated by 
mesh removal followed by implant of a biological mesh in ventral 
hernia patients.
In a retrospective case series, Albino et  al. reported on 27 
patients with an infected synthetic mesh treated with a multi-
staged approach (5). The initial surgical procedure consisted of 
abdominal exploration with debridement and mesh removal fol-
lowed by VAC® therapy. In the second stage, all patients underwent 
component separation and hernia repair reinforced by porcine 
acellular dermal matrix (PADM). Primary fascial closure was 
achieved in 21 (78%) of patients (19 meshes placed underlay and 2 
onlay). Bridging was performed in six (22%) patients. The average 
follow-up was 32 months (range 8–52 months). Six (22%) patients 
were found to have wound dehiscence and five (19%) of these had 
had clinical evidence of a surgical site infection. Wound healing 
was achieved in all patients in average after 8 weeks (2–60 weeks). 
Five (19%) patients developed a recurrent hernia. Both bridging 
and a postoperative infection were found to increase the risk of a 
hernia recurrence (p = 0.03 and 0.001, respectively).
In a single institution, Rosen et al. reported on 128 patients 
who had a single-stage reconstruction using a biological mesh 
in a contaminated field, of whom 45 (35%) were operated on 
for a simultaneous removal of a contaminated mesh (16). The 
mesh removal patients were not reported on separately. A total 
of 27% of operations were considered “dirty” according to the 
CDC classification and would probably include most of the 
mesh infected patients. A total of 66% had a retromuscular and 
31% an intraperitoneal mesh repair. Component separation was 
performed in 70% of patients and fascial closure was achieved in 
94%. Overall wound morbidity was seen in 61 patients (48%), of 
whom 28 were re-operated and 33 managed by local treatment 
of the infection. All wounds resolved within 60 days. At a mean 
follow-up of 22  months, 31% recurrences were seen. It can be 
concluded that using a biological mesh in these situations is safe, 
but the long-term durability seems to be less favorable, even when 
fascial closure has been achieved.
In a retrospective case review by Guerra, 13 patients had an 
infected synthetic mesh removed after former incisional hernia 
surgery (17). Mesh replacement was performed with a porcine-
derived acellular dermal matrix. The mean age was 60  years. 
Comorbidity was high. Facial closure was achieved in 11 and 
bridging in 2 patients. One wound infection, one seroma, and 
two hernia recurrences (both bridged patients) were observed at 
a median follow-up of 22 months. It was concluded that outcomes 
were favorable in high-risk patients with infected synthetic mesh 
if bridging was avoided.
Two patients were presented in a case report by Cavallaro 
et al. where one preperitoneal Prolene® mesh and one retromus-
cular polypropylene mesh were extracted and replaced with a 
retromuscular bovine pericardium graft. No complication and 
no recurrences were reported after 5 and 4  years, respectively. 
Closure of the gap was not reported on (18).
In a case report, Peppas et al. described drainage of an infected 
ePTFE together with a macro porous onlay polypropylene mesh 
for 1 month. The meshes were extracted and replaced by porcine 
onlay mesh (19). No complications were reported up to 6 months.
Two patients were reported by Coccolini et al. having a surgi-
cal site infection after a double-layered PP-e PTFE retromuscular 
FiGURe 1 | Algorithm for treatment of ventral/incisional hernia mesh infection.
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mesh repair (20). The first patient had a surgical site infection that 
discovered with substantial abdominal wall tissue loss 2  weeks 
after the operation for a recurrence. After 2 years of conservative 
treatment, the patient underwent mesh removal and retromus-
cular reconstruction using an acellular porcine dermal collagen 
cross-linked implant (CollaMend™). The second patient had an 
infection resulting in a sinus. The mesh was removed and replaced 
by a porcine mucosal non-cross-linked implant (Surgisis™). At 
37 respective 35 months after the operation, the patients demon-
strated no evidence of recurrence. The description of the technique 
used in these two patients implicates a bridging procedure (20).
DiSCUSSiOn
Mesh procedures are standard practice for surgical repair of both 
inguinal, ventral and incisional hernias (1–3). As the number of 
hernias treated worldwide continues to grow, also the number of 
hernia meshes implanted each year rise inexorably. Mesh infection 
rate in inguinal hernia surgery is below 1% and is not regarded 
as a clinical problem. However, surgeons often have to deal with 
mesh infections after ventral and incisional hernia surgery, which 
is estimated to be between 1 and 8% (6). The primary treatment 
modality is conservative. This is successful in eliminating mesh 
infection in over 50% of cases without mesh removal (7, 10). The 
most common bacterial agent is Staphylococcus aureus. With 
increasing proportion of methicillin resistance (MRSA), the 
treatment options in long-standing wound infections might be 
problematic to handle (11). There are no recommendations on 
how long a conservative regime is acceptable. Polypropylene and 
polyester meshes can be saved in a higher proportion that a lami-
nar mesh-like ePTFE. Extensive ePTFE mesh infections are best 
managed by mesh explantation (11). Pros and cons must though 
be weighed against each other according to the scenario presented. 
If conservative treatment fails, the mesh must be explanted (8, 15).
In mesh infection, biological meshes are increasingly used for 
replacement as synthetic meshes by some are regarded as con-
traindicated (5). The publications included in the present review 
demonstrated that there were three approaches that could be taken 
depending on the individual patient situation. The first option was 
to remove the infected mesh without a new implant. This is the most 
common option after inguinal hernia surgery, since the transversalis 
fascia is thickened by fibroses after the mesh removal (13). Using this 
approach, no inguinal hernia recurrence was seen on mean follow-up 
of 62 months in a case series (13). This does, however, not apply for 
incisional and ventral hernias. Tolino et al. reported on a recurrence 
rate of 23% after removal of an infected mesh following incisional 
hernia operation without reimplantation of a new mesh (8).
The second option was to replace the infected polypropylene 
mesh with a new polypropylene mesh (15). The short-term results 
showed a relative uneventful postoperative course after mesh 
replacement in 27 patients. Six (22%) patients developed a minor 
wound infection and were treated with dressings and antibiotics, 
five (19%) patients had wound infections requiring debridement 
and one required complete mesh removal. On follow-up, there 
were three hernia recurrences, one with an enterocutaneous 
fistula. Ninety-five percent of the patients undergoing mesh 
replacement were considered cured from chronic mesh infection 
after a mean follow-up of 74 months (15).
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The third option was to replace the explanted synthetic 
mesh with a biological mesh (5, 16–20). Long-term results were 
successful only if bridging was omitted (5, 16, 17). An unaccept-
ably high recurrence rate was observed following bridging with 
biological meshes (5, 16, 17). When bridging was avoided, good 
results were obtained for replacement of an infected synthetic 
mesh with a biological (5, 16, 17). An algorithm for treatment of 
ventral/incisional hernia mesh infection is presented in Figure 1.
It can be concluded that a mesh can be saved in more than 
half of patients suffering from an infection after implantation of 
a synthetic mesh for an incisional hernia. If mesh explanation is 
necessitated a replacement seems safe either using a synthetic or a 
biological mesh if fascia could be closed. Bridging seems to result 
in a high failure rate using a biological mesh. Further studies are 
needed to create a better evidence-based platform for specific 
therapeutic decision-making.
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APPenDiX
BioMesh Study Group
Ferdinand Köckerling (Chairman), Stavros Antoniou, René Fortelny, Frank A. Granderath, Markus Heiss, Franz Mayer, 
Marc Miserez, Agneta Montgomery, Salvador Morales-Conde, Filip Muysoms, Alexander Petter-Puchner, Rudolph Pointner, 
Neil Smart, Marciej Smietanski, and Bernd Stechemesser.
Aim
The BioMesh Study Group has set itself the task of identifying how best to use biological meshes for the various indications. The first 
step toward achieving that goal is to compile systematic reviews of the different indications on the basis of the existing literature. 
The available literature sources will be evaluated in accordance with the Oxford Centre for Evidence-Based Medicine-Levels of 
Evidence (March 2009). Next, based on the review findings, corresponding Statements and Recommendations are to be formulated 
in a Consensus Conference for the use of biological meshes for the different indications. The findings of the Consensus Conference 
are then to be summarized for a joint publication. This present publication is a part of the project undertaken by the BioMesh 
Study Group.
